• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.

作者信息

Fu K P, Lasinski E R, Zoganas H C, Kimble E F, Konopka E A

出版信息

J Antimicrob Chemother. 1984 Dec;14(6):633-40. doi: 10.1093/jac/14.6.633.

DOI:10.1093/jac/14.6.633
PMID:6520063
Abstract

The efficacy of rifampicin in treating a Bacteroides fragilis infection was investigated and compared to clindamycin and metronidazole in an experimental model of intra-abdominal abscess in mice. Rifampicin, when given subcutaneously, showed activity superior to that of clindamycin in reducing the incidence of abscess formation as well as the number of Bacteroides organisms recovered from the abscess, and rifampicin was comparable in efficacy to metronidazole when given orally at the same dose level. The comparative pharmacokinetic properties of rifampicin and clindamycin demonstrated that the peak serum and abscess levels reached with rifampicin were significantly higher than those of clindamycin. The half-life of rifampicin in serum and in the abscess was longer than that of clindamycin.

摘要

相似文献

1
Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
J Antimicrob Chemother. 1984 Dec;14(6):633-40. doi: 10.1093/jac/14.6.633.
2
Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections.利福平在脆弱拟杆菌和铜绿假单胞菌混合感染实验中的疗效。
J Antimicrob Chemother. 1985 May;15(5):579-85. doi: 10.1093/jac/15.5.579.
3
Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.环丙沙星对脆弱拟杆菌和大肠杆菌所致腹腔脓肿的治疗效果及药代动力学特性
Drugs Exp Clin Res. 1987;13(8):493-6.
4
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.新型喹诺酮类药物莫西沙星对小鼠脆弱拟杆菌所致实验性腹腔脓肿的治疗效果
Chemotherapy. 2004 Jun;50(2):76-80. doi: 10.1159/000077806.
5
Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice.
Chemotherapy. 1985;31(4):297-303. doi: 10.1159/000238351.
6
Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.抗微生物药物在脆弱拟杆菌所致实验性感染中的相对疗效及关键间隔时间
Arch Surg. 1983 Feb;118(2):181-4. doi: 10.1001/archsurg.1983.01390020037006.
7
Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice.泰利霉素治疗衰老小鼠实验性脆弱拟杆菌腹腔脓肿的疗效
Infez Med. 2004 Mar;12(1):44-50.
8
Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647).
Chemotherapy. 2001 Jan-Feb;47(1):43-9. doi: 10.1159/000048500.
9
Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.预防性抗生素对脆弱拟杆菌混合感染的影响。
Surg Gynecol Obstet. 1987 Dec;165(6):491-5.
10
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.喹诺酮类药物和克林霉素对小鼠体内脆弱拟杆菌和/或大肠杆菌感染的治疗效果:与体外药敏性的相关性
Antimicrob Agents Chemother. 1993 May;37(5):997-1000. doi: 10.1128/AAC.37.5.997.

引用本文的文献

1
Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.用新型糖脂去酰基环肽类药物雷莫拉宁治疗后,在胃肠道中重新定殖的耐万古霉素肠球菌的分子特征
J Clin Microbiol. 2002 Apr;40(4):1160-3. doi: 10.1128/JCM.40.4.1160-1163.2002.
2
Use of rifampin in nonstaphylococcal, nonmycobacterial disease.利福平在非葡萄球菌、非分枝杆菌疾病中的应用。
Antimicrob Agents Chemother. 1993 Jan;37(1):1-7. doi: 10.1128/AAC.37.1.1.